期刊
BRAIN
卷 141, 期 -, 页码 1263-1285出版社
OXFORD UNIV PRESS
DOI: 10.1093/brain/awx327
关键词
frontotemporal dementia; progressive supranuclear palsy; corticobasal degeneration; neurotransmitters; dementia
资金
- Holt Fellowship
- Wellcome Trust [JBR 103838]
- National Institute for Health Research Cambridge Biomedical Research Centre
- Cambridge Brain Bank
- MRC [MC_UU_00005/12, MC_U105597119] Funding Source: UKRI
- Medical Research Council [MC_UU_00005/12, MC_U105597119] Funding Source: researchfish
- Wellcome Trust [103838/Z/14/Z] Funding Source: researchfish
Frontotemporal lobar degeneration causes a spectrum of complex degenerative disorders including frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome, each of which is associated with changes in the principal neurotransmitter systems. We review the evidence for these neurochemical changes and propose that they contribute to symptomatology of frontotemporal lobar degeneration, over and above neuronal loss and atrophy. Despite the development of disease-modifying therapies, aiming to slow neuropathological progression, it remains important to advance symptomatic treatments to reduce the disease burden and improve patients' and carers' quality of life. We propose that targeting the selective deficiencies in neurotransmitter systems, including dopamine, noradrenaline, serotonin, acetylcholine, glutamate and gamma-aminobutyric acid is an important strategy towards this goal. We summarize the current evidence-base for pharmacological treatments and suggest strategies to improve the development of new, effective pharmacological treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据